Many doctors unknowingly prescribe drugs 'off-label,' study finds

Share this article:

A large number of physicians don't know when they are prescribing drugs, including antipsychotics, "off-label," according to a recent report.

"Off-label" refers to the practice of prescribing drugs in ways that are not approved by the Food and Drug Administration. Often, doctors will prescribe antipsychotics to treat Alzheimer's disease and dementia, even though he drug is intended for bipolar disorder and schizophrenia. But researchers in the journal Pharmacoepidemiology and Drug Safety say that nearly 20% of doctors will prescribe the drug Seroquel thinking it had been approved for dementia treatment, according to The New York Times. This occurred even though the drug carried a "black box" warning that it was dangerous for elderly patients with dementia.

The researchers from the University of Chicago also found that the average physician could correctly identify FDA approval status for only half the drugs they were asked about, according to the Times. One concern is that there is less scientific support for off-label uses as FDA-approved uses, one report author said.

 


Share this article:

More in News

Nursing home antipsychotic use has dipped nearly 19% under national effort, latest figures show

Nursing home antipsychotic use has dipped nearly 19% ...

The percent of long-stay nursing home residents receiving antipsychotic medication has decreased 18.8% under a nationwide initiative that started in 2012.

Jimmo succeeds in getting Medicare coverage, two years after landmark case ended

Glenda Jimmo has reached a settlement with the federal government and will finally receive Medicare coverage for claims that were denied in 2007, which led her to file a class-action lawsuit over the so-called "improvement standard."

Breier named new CEO at Kindred

Breier named new CEO at Kindred

Kindred Healthcare announced Thursday that it has chosen a new top executive to lead its push toward creating a mammoth national brand. Benjamin A. Breier, the company's current president and ...